DDInter1423 DDInter1840
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Pentobarbital {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Pentobarbital {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Pentobarbital {u} (Compound) upregulates {v} (Gene) PRKACA
PRKACA {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Pentobarbital {u} (Compound) downregulates {v} (Gene) TXLNA
TXLNA {u} (Gene) regulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Pentobarbital {u} (Compound) downregulates {v} (Gene) FABP5
FABP5 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Crizotinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Pentobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Pentobarbital (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Pentobarbital (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Pentobarbital (Compound) upregulates PRKACA (Gene) and PRKACA (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Pentobarbital (Compound) downregulates TXLNA (Gene) and TXLNA (Gene) regulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Pentobarbital (Compound) downregulates FABP5 (Gene) and FABP5 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib (Compound) binds SRC (Gene) and Crizotinib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)